The pharmaceutical industry faces significant challenges as Novo Nordisk and Eli Lilly grapple with trial setbacks and market ...

Mindy McCormick, 67, read that her insurer would soon stop covering the weight loss drug Wegovy, which she had been taking for more than two years. Nearly 9,000 people across the state had received ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

Zepbound, similar to Novo Nordisk’s anti-obesity and diabetes medication Ozempic, was approved to treat obstructive sleep ...

Novo Nordisk could also post results for semaglutide, the active ingredient in Wegovy and Ozempic, in treating patients with ...

US regulators on Friday approved the first drug treatment for sleep apnea, permitting the use of a weight-loss medication for ...

Illustration: Elizabeth Smelov Novo Nordisk shares dived Friday after an experimental anti-obesity treatment missed ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Shares of Ozempic-maker Novo Nordisk were down more than 20% in recent trade as the Danish drugmaker headed for its worst day since the 1980s. The stock took a hit after a late-stage trial showed that ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Skipping certain foods can help patients manage nausea and other side effects of the popular drugs, doctors say.